Evidence map›Paper›PMID 38977138›Full record

ArticleFree radical biology & medicine2024

Role of mitochondrial ribosomal protein L7/L12 (MRPL12) in diabetic ischemic heart disease.

Amit Kumar Rai, Shridhar Sanghvi, Natarajaseenivasan Suriya Muthukumaran, Dhananjie Chandrasekera, Ashlesha Kadam, Jahnavi Kishore, Ioannis D Kyriazis, Dhanendra Tomar, Devasena Ponnalagu, Vikram Shettigar and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Free radical biology & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Amit Kumar RaiAging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Shridhar SanghviDepartment of Physiology and Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Molecular Cellular and Developmental Biology, The Ohio State University, Columbus, OH, USA.
Natarajaseenivasan Suriya MuthukumaranAging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Dhananjie ChandrasekeraDepartment of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Ashlesha KadamSection of Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
Jahnavi KishoreAging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Ioannis D KyriazisDepartment of Biology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Dhanendra TomarSection of Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA.
Devasena PonnalaguDepartment of Physiology and Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Pharmacology, University of Washington, Seattle, WA, USA.
Vikram ShettigarAging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Mahmood KhanDorothy M. Davis Heart Lung and Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Harpreet SinghDepartment of Physiology and Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Dorothy M. Davis Heart Lung and Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
David GoukassianCardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Rajesh KatareDepartment of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Venkata Naga Srikanth GarikipatiAging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, USA; Department of Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: venkata.naga.srikanth.garikipati@temple.edu.

Funding

Role of small RNAs in ischemic tissue repairR01HL164794 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI Venkata Naga Srikanth Garikipati · 2023 to 2026
$2.2M
NHLBI NIH HHS R01 HL164794
6 · The paper itself

Abstract

backgroundMyocardial infarction (MI) is a significant cause of death in diabetic patients. Growing evidence suggests that mitochondrial dysfunction contributes to heart failure in diabetes. However, the molecular mechanisms of mitochondrial dysfunction mediating heart failure in diabetes are still poorly understood.

methodsWe examined MRPL12 levels in right atrial appendage tissues from diabetic patients undergoing coronary artery bypass graft (CABG) surgery. Using AC-16 cells overexpressing MRPL12 under normal and hyperglycemic conditions we performed mitochondrial functional assays OXPHOS, bioenergetics, mitochondrial membrane potential, ATP production and cell death.

resultsWe observed elevated MRPL12 levels in heart tissue samples from diabetic patients with ischemic heart disease compared to non-diabetic patients. Overexpression of MRPL12 under hyperglycemic conditions did not affect oxidative phosphorylation (OXPHOS) levels, cellular ATP levels, or cardiomyocyte cell death. However, notable impairment in mitochondrial membrane potential (MMP) was observed under hyperglycemic conditions, along with alterations in both basal respiration oxygen consumption rate (OCR) and maximal respiratory capacity OCR.

conclusionsOverall, our results suggest that MRPL12 may have a compensatory role in the diabetic myocardium with ischemic heart disease, suggesting that MRPL12 may implicate in the pathophysiology of MI in diabetes.

Indexed as

Cell Cycle ProteinsMembrane Potential, MitochondrialMyocardial IschemiaNuclear ProteinsOxidative PhosphorylationRibosomal ProteinsAdenosine TriphosphateAgedAnimalsAtrial AppendageCoronary Artery BypassDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedAdenosine TriphosphateCell Cycle ProteinsMitochondrial ProteinsMRPL12 protein, humanNuclear ProteinsRibosomal ProteinsAnd mitochondriaDiabetesMitochondrial membrane potentialMRPL12Oxygen consumption rate

Identifiers

PMID38977138
PMCPMC12935059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.